Completed NA INTERVENTIONAL 4-arm NCT04690920

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

Sponsor: University of Lahore

Conditions Corona Virus Disease 2019 (COVID-19)

Interventions Tocilizumab

Updated 3 times since 2021 Last updated: Dec 30, 2020 Started: Jul 23, 2020 Primary completion: Dec 10, 2020 Completion: Dec 10, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Corona Virus Disease 2019 (COVID-19) and is currently completed. University of Lahore leads this study, which shows 3 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Lahore

Data source: University of Lahore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan